Ekaterini C Tampaki1, Athanasios Tampakis1,2, Constantinos E Alifieris3,4,5, Dimitrios Krikelis6, Anastasia Pazaiti7, Michalis Kontos8, Dimitrios T Trafalis6,9. 1. Second Department Propaedeutic Surgery, "Laikon" General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece. 2. Department of Visceral Surgery, Basel University Hospital, Basel, Switzerland. 3. Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece. alifieris.k@gmail.com. 4. Department of Medical Oncology, "Henry Dunant" Hospital Center, Athens, Greece. alifieris.k@gmail.com. 5. Department of Surgery, General Hospital of Nea Ionia "Agia Olga-Konstantopouleion", Athens, Greece. alifieris.k@gmail.com. 6. Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece. 7. Breast Unit, 'Bioclinic' General Clinic of Athens, Athens, Greece. 8. First Department of Surgery, "Laikon" General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece. 9. Department of Medical Oncology, "Henry Dunant" Hospital Center, Athens, Greece.
Abstract
BACKGROUND: In the era of personalized therapy, targeted treatment in specific patient populations is mandated. OBJECTIVE: We evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer (LABC) with a monoclonal agent against vascular endothelial growth factor (VEGF), bevacizumab plus chemotherapy combination of liposomal doxorubicin, cyclophosphamide and paclitaxel (PLAC-B). METHODS: Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma. Patients had to have a measurable disease and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, with adequate hematologic, renal, and hepatic function. Patients received intravenous liposomal doxorubicin 30 mg/m2, cyclophosphamide 600 mg/m2, paclitaxel 120 mg/m2, and bevacizumab 8 mg/kg on day 1 of 15-day cycles for four cycles (four administrations as neoadjuvant treatment). The primary endpoint was complete clinical (cCR) and pathologic (pCR) response rates, while secondary endpoints included safety, breast-conserving surgery (BCS) conversion rate, and disease-free survival (DFS). RESULTS: Sixty-two women were enrolled; 20 were ER/PR+ and 42 had TNBC. All underwent surgery, six received mastectomy, and 56 (90.3%) received BCS, with an equal conversion rate from initial indication for mastectomy. cCR was 25.8%. pCR in the breast and axilla occurred in 24 patients (38.7%). pCR was 42.9% for TNBC and 30% for ER/PR+. Hematologic adverse events (AEs) included neutropenia (74.2% total; 22.6% grade 3 [G3]) and febrile neutropenia (6.5% G3); non-hematologic G3 AEs included nausea (6.5%), mucositis (9.7%), and infection (3.2%), all of which were managed without negative sequelae. Over a 3-year follow-up, all patients were alive and DFS was 87.1%. CONCLUSION: PLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated.
BACKGROUND: In the era of personalized therapy, targeted treatment in specific patient populations is mandated. OBJECTIVE: We evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer (LABC) with a monoclonal agent against vascular endothelial growth factor (VEGF), bevacizumab plus chemotherapy combination of liposomal doxorubicin, cyclophosphamide and paclitaxel (PLAC-B). METHODS:Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma. Patients had to have a measurable disease and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, with adequate hematologic, renal, and hepatic function. Patients received intravenous liposomal doxorubicin 30 mg/m2, cyclophosphamide 600 mg/m2, paclitaxel 120 mg/m2, and bevacizumab 8 mg/kg on day 1 of 15-day cycles for four cycles (four administrations as neoadjuvant treatment). The primary endpoint was complete clinical (cCR) and pathologic (pCR) response rates, while secondary endpoints included safety, breast-conserving surgery (BCS) conversion rate, and disease-free survival (DFS). RESULTS: Sixty-two women were enrolled; 20 were ER/PR+ and 42 had TNBC. All underwent surgery, six received mastectomy, and 56 (90.3%) received BCS, with an equal conversion rate from initial indication for mastectomy. cCR was 25.8%. pCR in the breast and axilla occurred in 24 patients (38.7%). pCR was 42.9% for TNBC and 30% for ER/PR+. Hematologic adverse events (AEs) included neutropenia (74.2% total; 22.6% grade 3 [G3]) and febrile neutropenia (6.5% G3); non-hematologic G3 AEs included nausea (6.5%), mucositis (9.7%), and infection (3.2%), all of which were managed without negative sequelae. Over a 3-year follow-up, all patients were alive and DFS was 87.1%. CONCLUSION: PLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated.
Authors: Kari Joanne Kansal; Laura Stewart Dominici; Sara M Tolaney; Steven J Isakoff; Barbara L Smith; Wei Jiang; Jane E Brock; Eric P Winer; Ian E Krop; Mehra Golshan Journal: Breast Cancer Res Treat Date: 2013-09-13 Impact factor: 4.872
Authors: Helena M Earl; Louise Hiller; Janet A Dunn; Clare Blenkinsop; Louise Grybowicz; Anne-Laure Vallier; Jean Abraham; Jeremy Thomas; Elena Provenzano; Luke Hughes-Davies; Ioannis Gounaris; Karen McAdam; Stephen Chan; Rizvana Ahmad; Tamas Hickish; Stephen Houston; Daniel Rea; John Bartlett; Carlos Caldas; David A Cameron; Larry Hayward Journal: Lancet Oncol Date: 2015-05-11 Impact factor: 41.316
Authors: B K Linderholm; H Hellborg; U Johansson; G Elmberger; L Skoog; J Lehtiö; R Lewensohn Journal: Ann Oncol Date: 2009-06-23 Impact factor: 32.976
Authors: R Bell; J Brown; M Parmar; M Toi; T Suter; G G Steger; X Pivot; J Mackey; C Jackisch; R Dent; P Hall; N Xu; L Morales; L Provencher; R Hegg; L Vanlemmens; A Kirsch; A Schneeweiss; N Masuda; F Overkamp; D Cameron Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: Ana Reis-Mendes; Félix Carvalho; Fernando Remião; Emília Sousa; Maria de Lourdes Bastos; Vera Marisa Costa Journal: Biomolecules Date: 2019-03-11